• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Cathie Wood-Lead Ark Invest Dumps $7.6M Worth Of Robinhood Shares Amid GameStop Buzz, Bitcoin Choppiness

    6/10/24 10:28:34 PM ET
    $ARCT
    $EXAS
    $HOOD
    $NTLA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical Specialities
    Health Care
    Get the next $ARCT alert in real time by email

    On Monday, Cathie Wood-led Ark Invest made a significant move by reducing its holdings in Robinhood Markets Inc (NASDAQ:HOOD). This decision came amidst a period of market fluctuations and followed a recent trend of the investment firm adjusting its portfolio.

    The HOOD Trade: Ark Invest’s decision to trim its position in Robinhood was executed through three of its ETFs. The ARK Fintech Innovation ETF (NYSE:ARKF) sold 31,827 shares, while the ARK Innovation ETF (NYSE:ARKK) and the ARK Next Generation Internet ETF (NYSE:ARKW) offloaded 215,675 and 76,299 shares respectively. Based on Robinhood’s closing price of $23.42 on Monday, the total value of the shares sold is approximately $7.6 million.

    The volatility in Robinhood shares comes amid a revival of the meme stock saga, recently Robinhood CEO Vlad Tenev announced that the company was prepared to handle any traffic influx resulting from a scheduled live stream from Roaring Kitty, also known as Keith Gill, who is famous for his investments in GameStop Corporation. The company also recently announced a $1 billion buyback, which contributed to the stock’s upward trend.

    Notably, the trade was executed in the background of a choppy cryptocurrency market when major coins like Bitcoin (CRYPTO: BTC) and Ethereum (CRYPTO: ETH) traded in the red.

    Other Key Trades:

    • Exact Sciences Corp (NASDAQ:EXAS): Sold shares via ARKG and shares via ARKK.
    • Arcturus Therapeutics Holdings Inc (NASDAQ:ARCT): Purchased shares via ARKG.
    • Teladoc Health Inc (NYSE:TDOC): Sold shares via ARKG.
    • Intellia Therapeutics Inc (NASDAQ:NTLA): Bought shares via ARKG and shares via ARKK.
    • Verve Therapeutics Inc (NASDAQ:VERV): Sold shares via ARKG and shares via ARKK. Veracyte Inc (NASDAQ:VCYT): Bought 5,804 shares via ARKG and shares via ARKK.

    Read Next: Investor Naval Ravikant Threatens To Sell All Tesla Holdings If CEO Musk’s Pay Plan Is Rejected But Says He’ll Buy More If Approved

    This story was generated using Benzinga Neuro and edited by Shivdeep Dhaliwal

    Get the next $ARCT alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ARCT
    $EXAS
    $HOOD
    $NTLA

    CompanyDatePrice TargetRatingAnalyst
    Robinhood Markets Inc.
    $HOOD
    4/20/2026$105.00 → $115.00Outperform
    Mizuho
    Veracyte Inc.
    $VCYT
    4/13/2026$45.00Buy
    Jefferies
    Robinhood Markets Inc.
    $HOOD
    4/8/2026$75.00Mkt Perform
    Keefe Bruyette
    Robinhood Markets Inc.
    $HOOD
    3/26/2026$88.00Buy
    Jefferies
    Arcturus Therapeutics Holdings Inc.
    $ARCT
    3/18/2026$22.00Buy
    B. Riley Securities
    Teladoc Health Inc.
    $TDOC
    3/10/2026$11.00Hold → Buy
    Deutsche Bank
    Intellia Therapeutics Inc.
    $NTLA
    3/2/2026Mkt Perform → Outperform
    William Blair
    Teladoc Health Inc.
    $TDOC
    2/26/2026$7.00Neutral → Buy
    BofA Securities
    More analyst ratings

    $ARCT
    $EXAS
    $HOOD
    $NTLA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    When Science Becomes an Asset: How Advancing Drug Pipelines Are Driving Real-Time Valuation in Biotech

    AUSTIN, Texas, April 20, 2026 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage: Biotechnology is undergoing a quiet but profound transformation, one that is reshaping how investors understand value in a sector historically defined by long timelines and uncertain outcomes. As drug candidates advance closer to commercialization, scientific progress is no longer viewed solely as research expenditure but increasingly as a measurable financial asset. This shift is being reinforced by fair-value accounting under U.S. GAAP, which allows life sciences companies to reflect clinical progress, probability of success and commercialization timing as measurable balance sheet value. Leading companies, s

    4/20/26 8:30:00 AM ET
    $ALNY
    $ARCT
    $DNLI
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    Teladoc Health to Announce First Quarter 2026 Financial Results

    NEW YORK, April 15, 2026 (GLOBE NEWSWIRE) -- Teladoc Health Inc. (NYSE:TDOC), the global leader in virtual care, announced that it will release first quarter 2026 results on Wednesday, April 29, 2026, after the market closes. In conjunction, the company will host a conference call to review results at 5:00 p.m. ET on the same day. Conference Call Details The conference call can be accessed by dialing (800) 715-9871 for U.S. participants and using the conference ID # 2214924. For international participants, please visit the following link for global dial-in numbers, using the same conference ID # 2214924: https://registrations.events/directory/international/itfs.html. A live audio webca

    4/15/26 4:05:00 PM ET
    $TDOC
    Medical/Nursing Services
    Health Care

    Veracyte to Release First Quarter 2026 Financial Results on May 5, 2026

    Veracyte, Inc. (NASDAQ:VCYT), a leading cancer diagnostics company, announced today that it will release financial results for the first quarter 2026 after the close of market on Tuesday, May 5, 2026. Company management will host a conference call and webcast to discuss financial results and provide a general business update at 4:30 p.m. Eastern Time on the same day. The conference call will be webcast live from the company's website and will be available via the following link: https://edge.media-server.com/mmc/p/293q6w6a. A webcast replay will be available following the conclusion of the live broadcast and will be accessible on the company's website at https://investor.veracyte.com/even

    4/14/26 4:05:00 PM ET
    $VCYT
    Medical Specialities
    Health Care

    $ARCT
    $EXAS
    $HOOD
    $NTLA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Bhatt Baiju

    4 - Robinhood Markets, Inc. (0001783879) (Issuer)

    4/20/26 6:07:42 PM ET
    $HOOD
    Investment Bankers/Brokers/Service
    Finance

    SEC Form 4 filed by Quirk Steven M.

    4 - Robinhood Markets, Inc. (0001783879) (Issuer)

    4/17/26 5:00:46 PM ET
    $HOOD
    Investment Bankers/Brokers/Service
    Finance

    SEC Form 4 filed by Verma Shiv

    4 - Robinhood Markets, Inc. (0001783879) (Issuer)

    4/17/26 5:00:12 PM ET
    $HOOD
    Investment Bankers/Brokers/Service
    Finance

    $ARCT
    $EXAS
    $HOOD
    $NTLA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Cohen Fred E bought $1,402,500 worth of shares (150,000 units at $9.35), increasing direct ownership by 261% to 207,453 units (SEC Form 4)

    4 - Intellia Therapeutics, Inc. (0001652130) (Issuer)

    1/7/26 4:05:06 PM ET
    $NTLA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Director Paulus Kenneth H bought $69,400 worth of shares (10,000 units at $6.94) (SEC Form 4)

    4 - Teladoc Health, Inc. (0001477449) (Issuer)

    11/17/25 4:05:05 PM ET
    $TDOC
    Medical/Nursing Services
    Health Care

    Director Chase William J bought $1,003,000 worth of shares (100,000 units at $10.03), increasing direct ownership by 288% to 134,693 units (SEC Form 4)

    4 - Intellia Therapeutics, Inc. (0001652130) (Issuer)

    8/22/25 4:30:14 PM ET
    $NTLA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $ARCT
    $EXAS
    $HOOD
    $NTLA
    SEC Filings

    View All

    SEC Form 144 filed by Robinhood Markets Inc.

    144 - Robinhood Markets, Inc. (0001783879) (Subject)

    4/15/26 4:55:06 PM ET
    $HOOD
    Investment Bankers/Brokers/Service
    Finance

    SEC Form 8-K filed by Intellia Therapeutics Inc.

    8-K - Intellia Therapeutics, Inc. (0001652130) (Filer)

    4/10/26 4:16:24 PM ET
    $NTLA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    SEC Form DEF 14A filed by Teladoc Health Inc.

    DEF 14A - Teladoc Health, Inc. (0001477449) (Filer)

    4/7/26 4:05:25 PM ET
    $TDOC
    Medical/Nursing Services
    Health Care

    $ARCT
    $EXAS
    $HOOD
    $NTLA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Mizuho reiterated coverage on Robinhood Markets with a new price target

    Mizuho reiterated coverage of Robinhood Markets with a rating of Outperform and set a new price target of $115.00 from $105.00 previously

    4/20/26 9:28:24 AM ET
    $HOOD
    Investment Bankers/Brokers/Service
    Finance

    Jefferies initiated coverage on Veracyte with a new price target

    Jefferies initiated coverage of Veracyte with a rating of Buy and set a new price target of $45.00

    4/13/26 9:01:55 AM ET
    $VCYT
    Medical Specialities
    Health Care

    Keefe Bruyette resumed coverage on Robinhood Markets with a new price target

    Keefe Bruyette resumed coverage of Robinhood Markets with a rating of Mkt Perform and set a new price target of $75.00

    4/8/26 8:38:05 AM ET
    $HOOD
    Investment Bankers/Brokers/Service
    Finance

    $ARCT
    $EXAS
    $HOOD
    $NTLA
    Leadership Updates

    Live Leadership Updates

    View All

    Teladoc Health Appoints Susan Salka, Experienced Healthcare Executive, to Its Board of Directors

    NEW YORK, March 30, 2026 (GLOBE NEWSWIRE) -- Teladoc Health (NYSE:TDOC), the global leader in virtual care, today announced the appointment of Susan Salka to its board of directors, effective immediately. Ms. Salka is the former president and CEO of AMN Healthcare Services, a provider of healthcare workforce technology solutions and staffing services to healthcare facilities across the US. She joins following the retirements of Eric Evans and Thomas McKinley and the appointment of Michael Smith. She will serve on the board's audit and compensation committees. "Susan brings a powerful combination of healthcare leadership and governance experience to the Board," said Kenneth H. Paulus, non‑

    3/30/26 4:30:00 PM ET
    $TDOC
    Medical/Nursing Services
    Health Care

    Veracyte Names Kevin Haas as Chief Development and Technology Officer

    Veracyte, Inc. (NASDAQ:VCYT), a leading cancer diagnostics company, announced today that Kevin Haas, Ph.D., has been appointed Chief Development and Technology Officer, a newly created leadership role designed to advance and scale the company's global product development strategy. Dr. Haas will join Veracyte on March 24, 2026, and he will be responsible for overseeing the company's end‑to‑end product development, spanning diagnostic assay development, software and bioinformatics, as well as the product development program office. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260316934398/en/Veracyte Names Kevin Haas as Chief De

    3/16/26 4:15:00 PM ET
    $VCYT
    Medical Specialities
    Health Care

    Quanterix Appoints Everett Cunningham as President and CEO Effective January 19, 2026

    Planned Leadership Transition Positions Company for Growth Company Expects to Exceed Revenue and Cash Guidance for the Full Year 2025 Quanterix Corporation ("Quanterix" or the "Company") (NASDAQ:QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced that its Board of Directors (the "Board") has appointed Everett Cunningham as the Company's next President and Chief Executive Officer and a member of the Board, effective January 19, 2026. Mr. Cunningham will succeed Masoud Toloue, who will continue to serve as Chief Executive Officer until Mr. Cunningham assumes the role on January 19, 2026. Following Mr. Cunningham

    1/8/26 4:30:00 PM ET
    $ARVN
    $DGX
    $EXAS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical Specialities
    Biotechnology: Laboratory Analytical Instruments

    $ARCT
    $EXAS
    $HOOD
    $NTLA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Verve Therapeutics Inc.

    SC 13G - Verve Therapeutics, Inc. (0001840574) (Subject)

    11/18/24 5:23:52 PM ET
    $VERV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Robinhood Markets Inc.

    SC 13G/A - Robinhood Markets, Inc. (0001783879) (Subject)

    11/14/24 7:04:24 AM ET
    $HOOD
    Investment Bankers/Brokers/Service
    Finance

    Amendment: SEC Form SC 13G/A filed by Robinhood Markets Inc.

    SC 13G/A - Robinhood Markets, Inc. (0001783879) (Subject)

    11/14/24 7:00:29 AM ET
    $HOOD
    Investment Bankers/Brokers/Service
    Finance

    $ARCT
    $EXAS
    $HOOD
    $NTLA
    Financials

    Live finance-specific insights

    View All

    Teladoc Health to Announce First Quarter 2026 Financial Results

    NEW YORK, April 15, 2026 (GLOBE NEWSWIRE) -- Teladoc Health Inc. (NYSE:TDOC), the global leader in virtual care, announced that it will release first quarter 2026 results on Wednesday, April 29, 2026, after the market closes. In conjunction, the company will host a conference call to review results at 5:00 p.m. ET on the same day. Conference Call Details The conference call can be accessed by dialing (800) 715-9871 for U.S. participants and using the conference ID # 2214924. For international participants, please visit the following link for global dial-in numbers, using the same conference ID # 2214924: https://registrations.events/directory/international/itfs.html. A live audio webca

    4/15/26 4:05:00 PM ET
    $TDOC
    Medical/Nursing Services
    Health Care

    Veracyte to Release First Quarter 2026 Financial Results on May 5, 2026

    Veracyte, Inc. (NASDAQ:VCYT), a leading cancer diagnostics company, announced today that it will release financial results for the first quarter 2026 after the close of market on Tuesday, May 5, 2026. Company management will host a conference call and webcast to discuss financial results and provide a general business update at 4:30 p.m. Eastern Time on the same day. The conference call will be webcast live from the company's website and will be available via the following link: https://edge.media-server.com/mmc/p/293q6w6a. A webcast replay will be available following the conclusion of the live broadcast and will be accessible on the company's website at https://investor.veracyte.com/even

    4/14/26 4:05:00 PM ET
    $VCYT
    Medical Specialities
    Health Care

    Robinhood Markets, Inc. to Announce First Quarter 2026 Results on April 28, 2026

    MENLO PARK, Calif., April 01, 2026 (GLOBE NEWSWIRE) -- Today, Robinhood Markets, Inc. ("Robinhood") (NASDAQ:HOOD) announced that it will release its first quarter 2026 financial results on Tuesday, April 28, 2026, after market close. Robinhood will host a video call with Chairman & Chief Executive Officer Vlad Tenev and Chief Financial Officer Shiv Verma to discuss its results at 2:00 PM PT / 5:00 PM ET on the same day. The video call and supporting materials will be available at investors.robinhood.com. The event will also be live streamed to YouTube and X.com via Robinhood's official channels, @RobinhoodApp, and within the Robinhood mobile app. Following the call, a replay and transcript

    4/1/26 4:05:00 PM ET
    $HOOD
    Investment Bankers/Brokers/Service
    Finance